Asthma
Conditions
Brief summary
The aim of this research is to investigate the extent and clinical relevance of small airways disease in severe eosinophilic asthma patients treated with anti-IL5/5R therapy.
Interventions
None listed
Sponsors
Frisius Medisch Centrum
Study design
Observational model
OTHER
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Severe asthma patients treated with anti-IL5/5R therapy (i.e. mepolizumab, benralizumab, reslizumab) for at least 4 months.
Exclusion criteria
* No information about lung function at baseline, or after both 4 months and 12 months. * No information about clinical response (i.e. number of exacerbations, reduction of mOCS/ maintenance oral corticosteroid dose, ACQ, AQLQ) after both 4 months and 12 months. * Treatment with another anti-IL5/5R therapy before
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Is change in FEF25-75 during anti-IL5/5R treatment associated with change in asthma control (measured with the asthma control questionnaire -ACQ-) in severe eosinophilic asthma patients after 4 months and after 12 months treatment? | 4 months and 12 months | Is change in FEF25-75 during anti-IL5/5R treatment associated with change in asthma control (measured with the asthma control questionnaire -ACQ-) in severe eosinophilic asthma patients after 4 months and after 12 months treatment? |
Countries
Netherlands
Contacts
Primary ContactAkke Nynke van der Meer, MD PhD
Backup ContactIlse Boudewijn, MD
Outcome results
None listed